MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/2045-824x-4-11

Медицинская библиотека · Vascular cell · 2012

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia.

Govindarajan Baskaran, Willoughby Laura, Band Hamid, Curatolo Adam S, Veledar Emir, Chen Suephy, Bonner Michael Y, Abel Martin-Garrido, Moses Marsha A, Arbiser Jack L

СтатьяПеревод в очереди

Аннотация

Tuberous sclerosis (TS) is a common autosomal-dominant disorder characterized by tumors of the skin, lung, brain, and kidneys. Monotherapy with rapamycin however resulted in partial regression of tumors, implying the involvement of additional pathways. We have previously implicated platelet-derived growth factor-BB in TS-related tumorigenesis, thus providing a rationale for a combination of mTOR/PDGF blockade using rapamycin and imatinib. Here, we test this combination using a well-established preclinical model of cutaneous tumorigenesis in TS, tsc2ang1 cells derived from a skin tumor from a mouse heterozygous for tsc2. Treatment of tsc2ang1 cells with a combination of rapamycin and imatinib led to an inhibition of proliferation compared with either vehicle treatment or treatment with rapamycin or imatinib monotherapy. Combination therapy also led to a decrease in Akt activation. Potent in vivo activity in animal experiments by combination therapy was noted, without toxicity to the animals. Our findings provide a rationale for the combined use of rapamycin and imatinib, both FDA approved drugs, for the treatment of TS.

Для цитирования: Govindarajan Baskaran, Willoughby Laura, Band Hamid, Curatolo Adam S, Veledar Emir, Chen Suephy, Bonner Michael Y, Abel Martin-Garrido, Moses Marsha A, Arbiser Jack L. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia.. Vascular cell. 2012. DOI: 10.1186/2045-824x-4-11.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.